Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- CETV +12.3%, TWTR +10.9%, IRBT +9.3%, LOGI +8.6%, ZIXI +8.4%, EW +8.2%, AMX +7%, TEL +5.8%, UVE +4.9%, WYNN +4.8%, OC +4.5%, KMT +4.2%, AUDC +4.1%, TSS +4%, MDCO +3.8%, RES +3.4%, PRGO +3.1%, (Perrigo announces restatement of previously issued forms 10-k and 10-q financial statements; reports Q1 results), WRK +3%, TKR +3%, CS +2.6%,TX +2.5%, NTB +2.5%, ARNC +2.5%, PRAH +2.4%, ANTM +2.1%, PTIE +1.8%, CMG +1.8%, CMG +1.8%, MC +1.7%, MKTX +1.7%, BAX +1.5%, BOFI +1.3%, AVY +1.3%, ROK +1.2%, LEA +1.2%, NOC +1.2%, JNPR +1.2%, HUN +1.1%, MDSO +1%, SC +1%, CRH +1%, NDAQ +0.9%
M&A news:
- DHT +2.8% (Frontline previously disclosed that it has submitted several proposals to the management and Board of DHT Holdings to effectuate a business combination between Frontline and DHT)
Other news:
- AKBA +28.1% (Akebia Therapeutics and Otsuka Pharma enter into a collaboration and license agreement for Europe, China and other territories; Akebia will receive $208 million or more in committed capital from Otsuka, including $73 million upon signing)
- MNOV +16.2% (presented exploratory interim data from MediciNova's ongoing clinical trial of MN-166 )
- OCN +7.9% (files 2 related motions that seek an early court culing that the CFPB is unconstitutional, and so its enforcement action against Ocwen should be thrown out)
- PETX +7.6% (ticking higher after confirming it recently met with FDA regarding the proposed manufacturing transfer of ENTYCE)
- NAVB +5.7% (higher on light volume after confirming it has been invited to present data at two 'major' upcoming conferences)
- ASYS +5.6% (receives follow-on order for the second phase of a multi-phase 1GW project, in addition to the order for the first phase announced in January 2017)
- DECK +5.5% (Board of Directors has initiated a process to review a broad range of strategic alternatives)
- MDCO +3.8% (Co and Alnylam Pharma (ALNY) announce that MDCO has agreed w/ the FDA on plans for the Phase III clinical program for inclisiran)
- COST +3.1% (reports special cash dividend of $7.00 per share and increase in quarterly cash dividend)
- ARI +3% (ticking higher; to join S&P SmallCap 600)
- PBF +2.5% (to join S&P MidCap 400)
- AMRI +2.1% (on sale related speculation)
- LVS +1.9% (WYNN sympathy)
- VRX +1.8% (announces that its Bausch + Lomb unit has received 510(k) clearance from the FDA for Vitesse)
- MGM +1.7% (WYNN sympathy)
- DDD +1.3% (3D Systems and United Therapeutics (UTHR) announce plans to develop solid-organ scaffolds for human transplants )
Analyst comments:
- APRI +16.4% (initiated with a Buy at Rodman & Renshaw)
- CONN +3.4% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)
- ATVI +1.2% (resumed with a Overweight at Pacific Crest)
- ABCB +0.9% (upgraded to Buy from Hold at SunTrust )
- GCO +0.8% (upgraded to Positive from Neutral at Susquehanna)
- BTU +0.8% (resumed with a Overweight at JP Morgan)
- PDS +0.7% (upgraded to Outperform from Mkt Perform at Raymond James)